Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Int J Mol Sci
2020 Jun 18;2112:. doi: 10.3390/ijms21124329.
Show Gene links
Show Anatomy links
Molecular Regulation of α3β4 Nicotinic Acetylcholine Receptors by Lupeol in Cardiovascular System.
Eom S
,
Kim C
,
Yeom HD
,
Lee J
,
Lee S
,
Baek YB
,
Na J
,
Park SI
,
Kim GY
,
Lee CM
,
Lee JH
.
???displayArticle.abstract???
Cardiovascular disease (CVD) occurs globally and has a high mortality rate. The highest risk factor for developing CVD is high blood pressure. Currently, natural products are emerging for the treatment of hypertension to avoid the side effects of drugs. Among existing natural products, lupeol is known to be effective against hypertension in animal experiments. However, there exists no study regarding the molecular physiological evidence against the effects of lupeol. Consequently, we investigated the interaction of lupeol with α3β4 nicotinic acetylcholine receptors (nAChRs). In this study, we performed a two-electrode voltage-clamp technique to investigate the effect of lupeol on the α3β4 nicotine acetylcholine receptor using the oocytes of Xenopus laevis. Coapplication of acetylcholine and lupeol inhibited the activity of α3β4 nAChRs in a concentration-dependent, voltage-independent, and reversible manner. We also conducted a mutational experiment to investigate the influence of residues of the α3 and β4 subunits on lupeol binding with nAChRs. Double mutants of α3β4 (I37A/N132A), nAChRs significantly attenuated the inhibitory effects of lupeol compared to wild-type α3β4 nAChRs. A characteristic of α3β4 nAChRs is their effect on transmission in the cardiac sympathetic ganglion. Overall, it is hypothesized that lupeol lowers hypertension by mediating its effects on α3β4 nAChRs. The interaction between lupeol and α3β4 nAChRs provides evidence against its effect on hypertension at the molecular-cell level. In conclusion, the inhibitory effect of lupeol is proposed as a novel therapeutic approach involving the antihypertensive targeting of α3β4 nAChRs. Furthermore, it is proposed that the molecular basis of the interaction between lupeol and α3β4 nAChRs would be helpful in cardiac-pharmacology research and therapeutics.
Figure 1. Structure and regulatory effects of lupeol on the α3β4 nicotinic acetylcholine receptors. (A) Chemical structure of lupeol (LP). (B) Summary of inhibitory effects of cotreatment of lupeol with acetylcholine. (C) Typically, 100 μM acetylcholine was applied with or without 30 μM lupeol. Mecamylamine (MEC) is an antagonist of nicotinic acetylcholine receptors (nAChRs). MEC shown at concentration of 10 μM. Arrow, point were LP was not treated onto oocyte surface but injected into cells. Traces representative of 5â9 separate oocytes from 3â5 different frogs. IAch recorded at holding potential of â80 mV before lupeol treatment. Small blue circle, cation; red one, lupeol.
Figure 2. Mechanism by which lupeol interacts with α3β4 nicotinic acetylcholine receptors. (A) Inward currents of trace for cotreatment of acetylcholine and lupeol in α3β4 nACh receptor. (B) Concentrationâresponse relationship induced by cotreatment of lupeol in α3β4 nACh receptors. Each point represents mean ± SEM (n = 10â13/group). (C) Representative currentâvoltage relationship obtained by using voltage ramps from â100 to +60 mV at holding potential of â80 mV. Voltage steps treated with 100 μM acetylcholine alone, and cotreated with 30 μM lupeol with ACh (n = 7â9 from four different frogs). (D) IAch induced by various concentrations of acetylcholine (â ) and cotreatment with 30 μM lupeol (â). Oocytes voltage-clamped at holding potential of â80 mV. Each point represents mean ± SEM (n = 10â13 from five different frogs).
Figure 3. Computational molecular modeling of lupeol docked to α3β4 nicotinic acetylcholine receptor. (A,C) Side views of docked lupeol in complex with nACh α3β4 receptor. (B,D) Top view of docking model.
Figure 4. Binding pocket view and docking results comparing wild type and mutant in lupeol docked to α3β4 nAChRs. (A) Lupeol located in binding pocket in extracellular area between Segments 1 and 2 of α3β4 nicotinic acetylcholine receptors. (B) Two-dimensional schematic presentation of predicted binding mode of lupeol in ligand-binding pocket. Ligands and important residues shown. (C,D) Binding interface and lupeol of wild type. (C) Four mutant channels in which mutations disturbed interaction of lupeol to varying degrees.
Figure 5. Effect of lupeol on double-mutant α3β4 nicotinic acetylcholine receptors. (AâC) Inward currents of concentrationâresponse relationship to coapplication of acetylcholine and lupeol with 10, 30, and 100 μM concentrations of oocytes expressing α3 (I37A) + Wild β4, Wild α3 + β4 (N132A), and α3β4 (I37A/N132A) nAChRs. (D) Concentrationâresponse graphs showing effect of different concentrations of lupeol on mutant α3β4 nACh receptors in presence of 100 μM acetylcholine. Each point is mean ± SEM (n = 6â7 from three different frogs). Additional half-inhibitory concentration, Hill coefficient, and Imax values described in Table 1.
Figure 1. Structure and regulatory effects of lupeol on the α3β4 nicotinic acetylcholine receptors. (A) Chemical structure of lupeol (LP). (B) Summary of inhibitory effects of cotreatment of lupeol with acetylcholine. (C) Typically, 100 μM acetylcholine was applied with or without 30 μM lupeol. Mecamylamine (MEC) is an antagonist of nicotinic acetylcholine receptors (nAChRs). MEC shown at concentration of 10 μM. Arrow, point were LP was not treated onto oocyte surface but injected into cells. Traces representative of 5â9 separate oocytes from 3â5 different frogs. IAch recorded at holding potential of â80 mV before lupeol treatment. Small blue circle, cation; red one, lupeol.
Figure 2. Mechanism by which lupeol interacts with α3β4 nicotinic acetylcholine receptors. (A) Inward currents of trace for cotreatment of acetylcholine and lupeol in α3β4 nACh receptor. (B) Concentrationâresponse relationship induced by cotreatment of lupeol in α3β4 nACh receptors. Each point represents mean ± SEM (n = 10â13/group). (C) Representative currentâvoltage relationship obtained by using voltage ramps from â100 to +60 mV at holding potential of â80 mV. Voltage steps treated with 100 μM acetylcholine alone, and cotreated with 30 μM lupeol with ACh (n = 7â9 from four different frogs). (D) IAch induced by various concentrations of acetylcholine (â ) and cotreatment with 30 μM lupeol (â). Oocytes voltage-clamped at holding potential of â80 mV. Each point represents mean ± SEM (n = 10â13 from five different frogs).
Figure 3. Computational molecular modeling of lupeol docked to α3β4 nicotinic acetylcholine receptor. (A,C) Side views of docked lupeol in complex with nACh α3β4 receptor. (B,D) Top view of docking model.
Figure 4. Binding pocket view and docking results comparing wild type and mutant in lupeol docked to α3β4 nAChRs. (A) Lupeol located in binding pocket in extracellular area between Segments 1 and 2 of α3β4 nicotinic acetylcholine receptors. (B) Two-dimensional schematic presentation of predicted binding mode of lupeol in ligand-binding pocket. Ligands and important residues shown. (C,D) Binding interface and lupeol of wild type. (C) Four mutant channels in which mutations disturbed interaction of lupeol to varying degrees.
Figure 5. Effect of lupeol on double-mutant α3β4 nicotinic acetylcholine receptors. (AâC) Inward currents of concentrationâresponse relationship to coapplication of acetylcholine and lupeol with 10, 30, and 100 μM concentrations of oocytes expressing α3 (I37A) + Wild β4, Wild α3 + β4 (N132A), and α3β4 (I37A/N132A) nAChRs. (D) Concentrationâresponse graphs showing effect of different concentrations of lupeol on mutant α3β4 nACh receptors in presence of 100 μM acetylcholine. Each point is mean ± SEM (n = 6â7 from three different frogs). Additional half-inhibitory concentration, Hill coefficient, and Imax values described in Table 1.
Alqahtani,
The pentacyclic triterpenoids in herbal medicines and their pharmacological activities in diabetes and diabetic complications.
2013, Pubmed
Alqahtani,
The pentacyclic triterpenoids in herbal medicines and their pharmacological activities in diabetes and diabetic complications.
2013,
Pubmed
Ardiansyah,
Lupeol supplementation improves blood pressure and lipid metabolism parameters in stroke-prone spontaneously hypertensive rats.
2012,
Pubmed
Bibevski,
Functional nicotinic acetylcholine receptors that mediate ganglionic transmission in cardiac parasympathetic neurons.
2000,
Pubmed
Cuny,
α-Conotoxins active at α3-containing nicotinic acetylcholine receptors and their molecular determinants for selective inhibition.
2018,
Pubmed
Dascal,
The use of Xenopus oocytes for the study of ion channels.
1987,
Pubmed
,
Xenbase
Dutertre,
Computational approaches to understand alpha-conotoxin interactions at neuronal nicotinic receptors.
2004,
Pubmed
Dutertre,
Beta2 subunit contribution to 4/7 alpha-conotoxin binding to the nicotinic acetylcholine receptor.
2005,
Pubmed
,
Xenbase
Guan,
Two-electrode voltage clamp.
2013,
Pubmed
,
Xenbase
J C Furtado,
Pentacyclic Triterpene Bioavailability: An Overview of In Vitro and In Vivo Studies.
2017,
Pubmed
Kjeldsen,
Hypertension and cardiovascular risk: General aspects.
2018,
Pubmed
Luo,
alpha-conotoxin AuIB selectively blocks alpha3 beta4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release.
1998,
Pubmed
,
Xenbase
Reitstetter,
Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure.
1999,
Pubmed
Rust,
Expression of neuronal nicotinic acetylcholine receptor subunit genes in the rat autonomic nervous system.
1994,
Pubmed
Sargent,
The diversity of neuronal nicotinic acetylcholine receptors.
1993,
Pubmed
Schreibmayer,
Voltage clamping of Xenopus laevis oocytes utilizing agarose-cushion electrodes.
1994,
Pubmed
,
Xenbase
Siddique,
Beneficial health effects of lupeol triterpene: a review of preclinical studies.
2011,
Pubmed
Sowers,
Diabetes, hypertension, and cardiovascular disease: an update.
2001,
Pubmed
Valentino,
Presynaptic inhibitory effect of acetylcholine in the hippocampus.
1981,
Pubmed
Vernino,
Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy.
2009,
Pubmed
Xi,
Sugar-sweetened beverages and risk of hypertension and CVD: a dose-response meta-analysis.
2015,
Pubmed